
The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-02-15 18:37:41 | INFO | fairseq_cli.train | Namespace(activation_dropout=0.0, activation_fn='relu', adam_betas='(0.9, 0.98)', adam_eps=1e-08, adaptive_input=False, adaptive_softmax_cutoff=None, adaptive_softmax_dropout=0, all_gather_list_size=16384, arch='transformer_vaswani_wmt_en_de_big', attention_dropout=0.0, best_checkpoint_metric='bleu', bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', clip_norm=0.0, cpu=False, criterion='label_smoothed_cross_entropy', cross_self_attention=False, curriculum=0, data='../../../data-bin/phrase7_0.5_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoder_attention_heads=16, decoder_embed_dim=1024, decoder_embed_path=None, decoder_ffn_embed_dim=4096, decoder_input_dim=1024, decoder_layerdrop=0, decoder_layers=6, decoder_layers_to_keep=None, decoder_learned_pos=False, decoder_normalize_before=False, decoder_output_dim=1024, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', dropout=0.2, empty_cache_freq=0, encoder_attention_heads=16, encoder_embed_dim=1024, encoder_embed_path=None, encoder_ffn_embed_dim=8192, encoder_layerdrop=0, encoder_layers=6, encoder_layers_to_keep=None, encoder_learned_pos=False, encoder_normalize_before=False, eval_bleu=True, eval_bleu_args='{"beam": 5, "max_len_a": 1.2, "max_len_b": 10}', eval_bleu_detok='moses', eval_bleu_detok_args=None, eval_bleu_print_samples=True, eval_bleu_remove_bpe='@@ ', eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, fixed_validation_seed=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, label_smoothing=0.1, layernorm_embedding=False, left_pad_source='True', left_pad_target='False', load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr=[5e-05], lr_scheduler='inverse_sqrt', max_epoch=10, max_sentences=None, max_sentences_valid=None, max_source_positions=1024, max_target_positions=1024, max_tokens=4096, max_tokens_valid=4096, max_update=0, maximize_best_checkpoint_metric=True, memory_efficient_bf16=False, memory_efficient_fp16=False, min_loss_scale=0.0001, min_lr=-1, model_parallel_size=1, no_cross_attention=False, no_epoch_checkpoints=True, no_last_checkpoints=False, no_progress_bar=False, no_save=False, no_save_optimizer_state=False, no_scale_embedding=False, no_seed_provided=True, no_token_positional_embeddings=False, nprocs_per_node=1, num_batch_buckets=0, num_workers=1, optimizer='adam', optimizer_overrides='{}', patience=-1, profile=False, quant_noise_pq=0, quant_noise_pq_block_size=8, quant_noise_scalar=0, quantization_config_path=None, required_batch_size_multiple=8, reset_dataloader=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=True, restore_file='../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt', save_dir='../checkpoints/EMEA_p_best_1', save_interval=1, save_interval_updates=0, scoring='bleu', seed=1, sentence_avg=False, share_all_embeddings=False, share_decoder_input_output_embed=True, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, stop_time_hours=0, target_lang=None, task='translation', tensorboard_logdir='', threshold_loss_scale=None, tie_adaptive_weights=False, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, update_freq=[1], upsample_primary=1, use_bmuf=False, use_old_adam=False, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, warmup_init_lr=-1, warmup_updates=4000, weight_decay=0.0001)
2021-02-15 18:37:41 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-15 18:37:41 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-15 18:37:41 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase7_0.5_EMEA/valid.de-en.de
2021-02-15 18:37:41 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase7_0.5_EMEA/valid.de-en.en
2021-02-15 18:37:41 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase7_0.5_EMEA valid de-en 151 examples
2021-02-15 18:37:47 | INFO | fairseq_cli.train | TransformerModel(
  (encoder): TransformerEncoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
  )
  (decoder): TransformerDecoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
    (output_projection): Linear(in_features=1024, out_features=42024, bias=False)
  )
)
2021-02-15 18:37:47 | INFO | fairseq_cli.train | model transformer_vaswani_wmt_en_de_big, criterion LabelSmoothedCrossEntropyCriterion
2021-02-15 18:37:47 | INFO | fairseq_cli.train | num. model params: 312778752 (num. trained: 312778752)
2021-02-15 18:37:57 | INFO | fairseq.trainer | detected shared parameter: decoder.embed_tokens.weight <- decoder.output_projection.weight
2021-02-15 18:37:57 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-15 18:37:57 | INFO | fairseq.utils | rank   0: capabilities =  7.0  ; total memory = 32.000 GB ; name = GRID V100D-32Q                          
2021-02-15 18:37:57 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-15 18:37:57 | INFO | fairseq_cli.train | training on 1 devices (GPUs/TPUs)
2021-02-15 18:37:57 | INFO | fairseq_cli.train | max tokens per GPU = 4096 and max sentences per GPU = None
2021-02-15 18:38:07 | INFO | fairseq.trainer | loaded checkpoint ../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt (epoch 16 @ 0 updates)
2021-02-15 18:38:07 | INFO | fairseq.trainer | loading train data for epoch 1
2021-02-15 18:38:07 | INFO | fairseq.data.data_utils | loaded 133090 examples from: ../../../data-bin/phrase7_0.5_EMEA/train.de-en.de
2021-02-15 18:38:08 | INFO | fairseq.data.data_utils | loaded 133090 examples from: ../../../data-bin/phrase7_0.5_EMEA/train.de-en.en
2021-02-15 18:38:08 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase7_0.5_EMEA train de-en 133090 examples
2021-02-15 18:38:09 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-15 18:38:10 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 64.0
2021-02-15 18:38:10 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 32.0
2021-02-15 18:38:10 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 16.0
2021-02-15 18:38:10 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 8.0
2021-02-15 18:38:11 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 4.0
2021-02-15 18:38:11 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 2.0
2021-02-15 18:38:12 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 1.0
2021-02-15 18:38:30 | INFO | train_inner | epoch 001:    107 / 228 loss=4.189, nll_loss=2.555, ppl=5.88, wps=17626.9, ups=5.11, wpb=3457.8, bsz=603.7, num_updates=100, lr=1.25e-06, gnorm=13.352, loss_scale=1, train_wall=19, wall=33
2021-02-15 18:38:50 | INFO | train_inner | epoch 001:    207 / 228 loss=3.674, nll_loss=1.987, ppl=3.96, wps=17723.8, ups=5.16, wpb=3432.7, bsz=536.7, num_updates=200, lr=2.5e-06, gnorm=7.481, loss_scale=1, train_wall=19, wall=53
2021-02-15 18:38:54 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:38:55 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-15 18:38:55 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:38:56 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-15 18:38:56 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:38:57 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-15 18:38:57 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:39:00 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (one study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit has actrapid shown in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-15 18:39:00 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:39:00 | INFO | valid | epoch 001 | valid on 'valid' subset | loss 3.839 | nll_loss 2.125 | ppl 4.36 | bleu 33.48 | wps 701.3 | wpb 1083 | bsz 37.8 | num_updates 221
2021-02-15 18:39:00 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:39:24 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 1 @ 221 updates, score 33.48) (writing took 23.975289246998727 seconds)
2021-02-15 18:39:24 | INFO | fairseq_cli.train | end of epoch 1 (average epoch stats below)
2021-02-15 18:39:24 | INFO | train | epoch 001 | loss 3.912 | nll_loss 2.251 | ppl 4.76 | wps 10310.2 | ups 3 | wpb 3439.6 | bsz 573.9 | num_updates 221 | lr 2.7625e-06 | gnorm 10.099 | loss_scale 2 | train_wall 44 | wall 87
2021-02-15 18:39:24 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-15 18:39:40 | INFO | train_inner | epoch 002:     79 / 228 loss=3.458, nll_loss=1.75, ppl=3.36, wps=6842.4, ups=2, wpb=3424.7, bsz=596.3, num_updates=300, lr=3.75e-06, gnorm=5.192, loss_scale=1, train_wall=19, wall=103
2021-02-15 18:39:59 | INFO | train_inner | epoch 002:    179 / 228 loss=3.297, nll_loss=1.562, ppl=2.95, wps=17679, ups=5.16, wpb=3426.8, bsz=577.6, num_updates=400, lr=5e-06, gnorm=3.623, loss_scale=1, train_wall=19, wall=122
2021-02-15 18:40:09 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:40:09 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-15 18:40:09 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:40:10 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used in conjunction with long acting insulin preparations.
2021-02-15 18:40:10 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:40:11 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-15 18:40:11 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:40:15 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is regulated.What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with Actrapid.
2021-02-15 18:40:15 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:40:15 | INFO | valid | epoch 002 | valid on 'valid' subset | loss 3.669 | nll_loss 1.921 | ppl 3.79 | bleu 37.62 | wps 660.3 | wpb 1083 | bsz 37.8 | num_updates 449 | best_bleu 37.62
2021-02-15 18:40:15 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:40:38 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 2 @ 449 updates, score 37.62) (writing took 22.921206790953875 seconds)
2021-02-15 18:40:38 | INFO | fairseq_cli.train | end of epoch 2 (average epoch stats below)
2021-02-15 18:40:38 | INFO | train | epoch 002 | loss 3.282 | nll_loss 1.548 | ppl 2.92 | wps 10698.9 | ups 3.1 | wpb 3449.9 | bsz 583.7 | num_updates 449 | lr 5.6125e-06 | gnorm 3.806 | loss_scale 1 | train_wall 44 | wall 161
2021-02-15 18:40:38 | INFO | fairseq_cli.train | begin training epoch 2
2021-02-15 18:40:48 | INFO | train_inner | epoch 003:     51 / 228 loss=3.058, nll_loss=1.292, ppl=2.45, wps=7087.3, ups=2.05, wpb=3458.5, bsz=571.8, num_updates=500, lr=6.25e-06, gnorm=2.975, loss_scale=1, train_wall=19, wall=171
2021-02-15 18:41:07 | INFO | train_inner | epoch 003:    151 / 228 loss=3.019, nll_loss=1.247, ppl=2.37, wps=18067.2, ups=5.16, wpb=3502.8, bsz=628.3, num_updates=600, lr=7.5e-06, gnorm=2.869, loss_scale=1, train_wall=19, wall=190
2021-02-15 18:41:22 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:41:23 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:41:23 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:41:24 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used in conjunction with long-acting insulin preparations.
2021-02-15 18:41:24 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:41:25 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy that are usually reversible.
2021-02-15 18:41:25 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:41:27 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c) that indicates how well blood glucose is regulated.What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 month treatment with Actrapid.
2021-02-15 18:41:27 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:41:27 | INFO | valid | epoch 003 | valid on 'valid' subset | loss 3.564 | nll_loss 1.799 | ppl 3.48 | bleu 42.24 | wps 836.3 | wpb 1083 | bsz 37.8 | num_updates 677 | best_bleu 42.24
2021-02-15 18:41:27 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:41:51 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 3 @ 677 updates, score 42.24) (writing took 23.81799870915711 seconds)
2021-02-15 18:41:51 | INFO | fairseq_cli.train | end of epoch 3 (average epoch stats below)
2021-02-15 18:41:51 | INFO | train | epoch 003 | loss 3.001 | nll_loss 1.225 | ppl 2.34 | wps 10733.9 | ups 3.11 | wpb 3449.9 | bsz 583.7 | num_updates 677 | lr 8.4625e-06 | gnorm 2.871 | loss_scale 1 | train_wall 44 | wall 234
2021-02-15 18:41:51 | INFO | fairseq_cli.train | begin training epoch 3
2021-02-15 18:41:56 | INFO | train_inner | epoch 004:     23 / 228 loss=2.93, nll_loss=1.144, ppl=2.21, wps=6991.6, ups=2.07, wpb=3379.5, bsz=557.6, num_updates=700, lr=8.75e-06, gnorm=2.69, loss_scale=1, train_wall=19, wall=238
2021-02-15 18:42:15 | INFO | train_inner | epoch 004:    123 / 228 loss=2.887, nll_loss=1.093, ppl=2.13, wps=17926.2, ups=5.16, wpb=3477.1, bsz=583.3, num_updates=800, lr=1e-05, gnorm=2.648, loss_scale=1, train_wall=19, wall=258
2021-02-15 18:42:35 | INFO | train_inner | epoch 004:    223 / 228 loss=2.748, nll_loss=0.941, ppl=1.92, wps=17811.8, ups=5.13, wpb=3473.7, bsz=586.6, num_updates=900, lr=1.125e-05, gnorm=2.509, loss_scale=1, train_wall=19, wall=277
2021-02-15 18:42:36 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:42:36 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:42:36 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:42:37 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used concomitantly with long-acting insulin products.
2021-02-15 18:42:37 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:42:38 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy that are usually reversible.
2021-02-15 18:42:38 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:42:41 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (Insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c) that indicates how well blood glucose is regulated.What benefit has Actrapid shown in these trials? Concentrations of HbA1c have remained relatively stable during the 6 month treatment with Actrapid.
2021-02-15 18:42:41 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:42:41 | INFO | valid | epoch 004 | valid on 'valid' subset | loss 3.525 | nll_loss 1.752 | ppl 3.37 | bleu 43.93 | wps 811 | wpb 1083 | bsz 37.8 | num_updates 905 | best_bleu 43.93
2021-02-15 18:42:41 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:43:04 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 4 @ 905 updates, score 43.93) (writing took 22.92235900927335 seconds)
2021-02-15 18:43:04 | INFO | fairseq_cli.train | end of epoch 4 (average epoch stats below)
2021-02-15 18:43:04 | INFO | train | epoch 004 | loss 2.817 | nll_loss 1.017 | ppl 2.02 | wps 10849.8 | ups 3.14 | wpb 3449.9 | bsz 583.7 | num_updates 905 | lr 1.13125e-05 | gnorm 2.584 | loss_scale 1 | train_wall 44 | wall 306
2021-02-15 18:43:04 | INFO | fairseq_cli.train | begin training epoch 4
2021-02-15 18:43:22 | INFO | train_inner | epoch 005:     95 / 228 loss=2.692, nll_loss=0.878, ppl=1.84, wps=7228.4, ups=2.1, wpb=3445, bsz=623.9, num_updates=1000, lr=1.25e-05, gnorm=2.402, loss_scale=1, train_wall=19, wall=325
2021-02-15 18:43:42 | INFO | train_inner | epoch 005:    195 / 228 loss=2.646, nll_loss=0.822, ppl=1.77, wps=17650.1, ups=5.11, wpb=3455.9, bsz=544.4, num_updates=1100, lr=1.375e-05, gnorm=2.279, loss_scale=1, train_wall=19, wall=345
2021-02-15 18:43:48 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:43:49 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-15 18:43:49 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:43:50 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used concomitantly with long-acting insulin products.
2021-02-15 18:43:50 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:43:51 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-15 18:43:51 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:43:53 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body cannot process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (Insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c) that indicates how well the blood glucose is. What benefit has Actrapid shown in these trials? Concentrations of HbA1c have remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-15 18:43:53 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:43:53 | INFO | valid | epoch 005 | valid on 'valid' subset | loss 3.533 | nll_loss 1.756 | ppl 3.38 | bleu 46.24 | wps 848.7 | wpb 1083 | bsz 37.8 | num_updates 1133 | best_bleu 46.24
2021-02-15 18:43:53 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:44:17 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 5 @ 1133 updates, score 46.24) (writing took 24.112338481470942 seconds)
2021-02-15 18:44:17 | INFO | fairseq_cli.train | end of epoch 5 (average epoch stats below)
2021-02-15 18:44:17 | INFO | train | epoch 005 | loss 2.671 | nll_loss 0.852 | ppl 1.8 | wps 10677 | ups 3.09 | wpb 3449.9 | bsz 583.7 | num_updates 1133 | lr 1.41625e-05 | gnorm 2.366 | loss_scale 1 | train_wall 44 | wall 380
2021-02-15 18:44:17 | INFO | fairseq_cli.train | begin training epoch 5
2021-02-15 18:44:30 | INFO | train_inner | epoch 006:     67 / 228 loss=2.647, nll_loss=0.823, ppl=1.77, wps=7065.6, ups=2.06, wpb=3430.6, bsz=574.2, num_updates=1200, lr=1.5e-05, gnorm=2.379, loss_scale=1, train_wall=19, wall=393
2021-02-15 18:44:50 | INFO | train_inner | epoch 006:    167 / 228 loss=2.573, nll_loss=0.74, ppl=1.67, wps=17523.8, ups=5.16, wpb=3397.2, bsz=572, num_updates=1300, lr=1.625e-05, gnorm=2.377, loss_scale=1, train_wall=19, wall=413
2021-02-15 18:45:02 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:45:03 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-15 18:45:03 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:45:03 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used concomitantly with long-acting insulin preparations.
2021-02-15 18:45:03 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:45:04 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-15 18:45:04 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:45:07 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials in 1,954 patients) and in patients with type 2 diabetes in whom the body cannot process insulin effectively (a trial in 182 patients) .In the trials, Actrapide was compared with a human insulin analogue (Insulin Aspart) by measuring the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood glucose is regulated.What benefit has Actrapid shown in these trials? Concentrations of HbA1c have remained relatively stable during the 6 month treatment with Actrapid.
2021-02-15 18:45:07 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:45:07 | INFO | valid | epoch 006 | valid on 'valid' subset | loss 3.534 | nll_loss 1.759 | ppl 3.38 | bleu 48.33 | wps 832.9 | wpb 1083 | bsz 37.8 | num_updates 1361 | best_bleu 48.33
2021-02-15 18:45:07 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:45:29 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 6 @ 1361 updates, score 48.33) (writing took 21.944919938221574 seconds)
2021-02-15 18:45:29 | INFO | fairseq_cli.train | end of epoch 6 (average epoch stats below)
2021-02-15 18:45:29 | INFO | train | epoch 006 | loss 2.555 | nll_loss 0.72 | ppl 1.65 | wps 10993.1 | ups 3.19 | wpb 3449.9 | bsz 583.7 | num_updates 1361 | lr 1.70125e-05 | gnorm 2.169 | loss_scale 1 | train_wall 44 | wall 452
2021-02-15 18:45:29 | INFO | fairseq_cli.train | begin training epoch 6
2021-02-15 18:45:37 | INFO | train_inner | epoch 007:     39 / 228 loss=2.444, nll_loss=0.597, ppl=1.51, wps=7521.4, ups=2.14, wpb=3522.1, bsz=607.5, num_updates=1400, lr=1.75e-05, gnorm=1.675, loss_scale=1, train_wall=19, wall=459
2021-02-15 18:45:56 | INFO | train_inner | epoch 007:    139 / 228 loss=2.473, nll_loss=0.627, ppl=1.54, wps=18049.9, ups=5.16, wpb=3498, bsz=566.5, num_updates=1500, lr=1.875e-05, gnorm=2.039, loss_scale=1, train_wall=19, wall=479
2021-02-15 18:46:13 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:46:14 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-15 18:46:14 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:46:15 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used concomitantly with long-acting insulin products.
2021-02-15 18:46:15 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:46:16 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-15 18:46:16 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:46:18 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials in 1,954 patients) and in patients with type 2 diabetes in whom the body cannot process insulin effectively (a trial in 182 patients) .The studies compared Actrapid with a human insulin analogue (Insulin Aspart) by measuring the level in the blood of a substance called glycosylated haemoglobin (HbA1c) that indicates how well the blood glucose is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 month treatment with Actrapid.
2021-02-15 18:46:18 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:46:18 | INFO | valid | epoch 007 | valid on 'valid' subset | loss 3.554 | nll_loss 1.782 | ppl 3.44 | bleu 49.83 | wps 872.7 | wpb 1083 | bsz 37.8 | num_updates 1589 | best_bleu 49.83
2021-02-15 18:46:18 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:46:41 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 7 @ 1589 updates, score 49.83) (writing took 23.041481168940663 seconds)
2021-02-15 18:46:41 | INFO | fairseq_cli.train | end of epoch 7 (average epoch stats below)
2021-02-15 18:46:41 | INFO | train | epoch 007 | loss 2.459 | nll_loss 0.613 | ppl 1.53 | wps 10880.1 | ups 3.15 | wpb 3449.9 | bsz 583.7 | num_updates 1589 | lr 1.98625e-05 | gnorm 2.014 | loss_scale 1 | train_wall 44 | wall 524
2021-02-15 18:46:41 | INFO | fairseq_cli.train | begin training epoch 7
2021-02-15 18:46:44 | INFO | train_inner | epoch 008:     11 / 228 loss=2.444, nll_loss=0.599, ppl=1.51, wps=7153.5, ups=2.1, wpb=3400.8, bsz=582.4, num_updates=1600, lr=2e-05, gnorm=2.049, loss_scale=1, train_wall=19, wall=526
2021-02-15 18:47:03 | INFO | train_inner | epoch 008:    111 / 228 loss=2.416, nll_loss=0.565, ppl=1.48, wps=17940.7, ups=5.18, wpb=3463.8, bsz=616.2, num_updates=1700, lr=2.125e-05, gnorm=1.975, loss_scale=1, train_wall=19, wall=546
2021-02-15 18:47:22 | INFO | train_inner | epoch 008:    211 / 228 loss=2.347, nll_loss=0.488, ppl=1.4, wps=17777, ups=5.14, wpb=3456.3, bsz=574.5, num_updates=1800, lr=2.25e-05, gnorm=1.805, loss_scale=1, train_wall=19, wall=565
2021-02-15 18:47:26 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:47:26 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which may cause allergic reactions.
2021-02-15 18:47:26 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:47:27 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used concomitantly with long-acting insulin preparations.
2021-02-15 18:47:27 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:47:28 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-15 18:47:28 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:47:31 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was studied in patients with type 1 diabetes, in whom the pancreas is unable to produce insulin (two trials with 1,954 patients), and in patients with type 2 diabetes, in whom the body cannot process insulin effectively (a trial in 182 patients) .The studies compared Actrapide with a human insulin analogue (Insulin Aspart) by measuring the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood glucose is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 month treatment with Actrapid.
2021-02-15 18:47:31 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:47:31 | INFO | valid | epoch 008 | valid on 'valid' subset | loss 3.579 | nll_loss 1.818 | ppl 3.53 | bleu 48.96 | wps 834.8 | wpb 1083 | bsz 37.8 | num_updates 1817 | best_bleu 49.83
2021-02-15 18:47:31 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:47:43 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_last.pt (epoch 8 @ 1817 updates, score 48.96) (writing took 11.994141031987965 seconds)
2021-02-15 18:47:43 | INFO | fairseq_cli.train | end of epoch 8 (average epoch stats below)
2021-02-15 18:47:43 | INFO | train | epoch 008 | loss 2.383 | nll_loss 0.528 | ppl 1.44 | wps 12797.3 | ups 3.71 | wpb 3449.9 | bsz 583.7 | num_updates 1817 | lr 2.27125e-05 | gnorm 1.87 | loss_scale 1 | train_wall 44 | wall 585
2021-02-15 18:47:43 | INFO | fairseq_cli.train | begin training epoch 8
2021-02-15 18:47:59 | INFO | train_inner | epoch 009:     83 / 228 loss=2.312, nll_loss=0.449, ppl=1.37, wps=9407.6, ups=2.73, wpb=3446.4, bsz=571.9, num_updates=1900, lr=2.375e-05, gnorm=1.528, loss_scale=1, train_wall=19, wall=602
2021-02-15 18:48:18 | INFO | train_inner | epoch 009:    183 / 228 loss=2.328, nll_loss=0.468, ppl=1.38, wps=17750.5, ups=5.2, wpb=3410.8, bsz=563, num_updates=2000, lr=2.5e-05, gnorm=1.726, loss_scale=1, train_wall=19, wall=621
2021-02-15 18:48:27 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:48:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which may cause allergic reactions.
2021-02-15 18:48:28 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:48:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used concomitantly with long-acting insulin preparations.
2021-02-15 18:48:28 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:48:29 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-15 18:48:29 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:48:32 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was studied in patients with type 1 diabetes, in whom the pancreas is unable to produce insulin (two trials with 1,954 patients), and in patients with type 2 diabetes, in whom the body cannot process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (Insulin Aspart) by measuring the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood glucose is controlled. What benefit has Actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 month treatment with Actrapide.
2021-02-15 18:48:32 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:48:32 | INFO | valid | epoch 009 | valid on 'valid' subset | loss 3.586 | nll_loss 1.826 | ppl 3.54 | bleu 50.46 | wps 857.7 | wpb 1083 | bsz 37.8 | num_updates 2045 | best_bleu 50.46
2021-02-15 18:48:32 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:48:57 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_best.pt (epoch 9 @ 2045 updates, score 50.46) (writing took 24.967967745848 seconds)
2021-02-15 18:48:57 | INFO | fairseq_cli.train | end of epoch 9 (average epoch stats below)
2021-02-15 18:48:57 | INFO | train | epoch 009 | loss 2.321 | nll_loss 0.46 | ppl 1.38 | wps 10612.4 | ups 3.08 | wpb 3449.9 | bsz 583.7 | num_updates 2045 | lr 2.55625e-05 | gnorm 1.651 | loss_scale 1 | train_wall 43 | wall 660
2021-02-15 18:48:57 | INFO | fairseq_cli.train | begin training epoch 9
2021-02-15 18:49:08 | INFO | train_inner | epoch 010:     55 / 228 loss=2.318, nll_loss=0.459, ppl=1.37, wps=7088.6, ups=2.03, wpb=3496.7, bsz=640.4, num_updates=2100, lr=2.625e-05, gnorm=1.711, loss_scale=1, train_wall=19, wall=670
2021-02-15 18:49:27 | INFO | train_inner | epoch 010:    155 / 228 loss=2.263, nll_loss=0.395, ppl=1.31, wps=17597, ups=5.19, wpb=3389.3, bsz=529.8, num_updates=2200, lr=2.75e-05, gnorm=1.484, loss_scale=1, train_wall=19, wall=690
2021-02-15 18:49:41 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-15 18:49:42 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which may cause allergic reactions.
2021-02-15 18:49:42 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-15 18:49:42 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used concomitantly with long-acting insulin preparations.
2021-02-15 18:49:42 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-15 18:49:43 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-15 18:49:43 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-15 18:49:46 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was studied in patients with type 1 diabetes, in whom the pancreas is unable to produce insulin (two trials with 1,954 patients), and in patients with type 2 diabetes, in whom the body cannot effectively process insulin (a trial with 182 patients). In the trials, Actrapide was compared with a human insulin analogue (insulin Aspart) by measuring in the blood for six months the level of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood glucose is controlled. What benefit has Actrapid shown in these trials?
2021-02-15 18:49:46 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-15 18:49:46 | INFO | valid | epoch 010 | valid on 'valid' subset | loss 3.632 | nll_loss 1.889 | ppl 3.7 | bleu 49.34 | wps 851.1 | wpb 1083 | bsz 37.8 | num_updates 2273 | best_bleu 50.46
2021-02-15 18:49:46 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-15 18:49:54 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_best_1/checkpoint_last.pt (epoch 10 @ 2273 updates, score 49.34) (writing took 7.693039685487747 seconds)
2021-02-15 18:49:54 | INFO | fairseq_cli.train | end of epoch 10 (average epoch stats below)
2021-02-15 18:49:54 | INFO | train | epoch 010 | loss 2.276 | nll_loss 0.411 | ppl 1.33 | wps 13835.6 | ups 4.01 | wpb 3449.9 | bsz 583.7 | num_updates 2273 | lr 2.84125e-05 | gnorm 1.56 | loss_scale 1 | train_wall 44 | wall 716
2021-02-15 18:49:54 | INFO | fairseq_cli.train | done training in 705.1 seconds


###############################################################################
Peregrine Cluster
Job 18005994 for user 's3475743'
Finished at: Mon Feb 15 18:49:59 CET 2021

Job details:
============

Job ID              : 18005994
Name                : EMEA_p_best_1
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu39
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-02-15T18:34:03
Start               : 2021-02-15T18:37:15
End                 : 2021-02-15T18:49:59
Reserved walltime   : 23:55:00
Used walltime       : 00:12:44
Used CPU time       : 00:13:45 (efficiency:  9.01%)
% User (Computation): 61.92%
% System (I/O)      : 38.08%
Mem reserved        : 32G/node
Max Mem used        : 5.61G (pg-gpu39)
Max Disk Write      : 40.96K (pg-gpu39)
Max Disk Read       : 2.30M (pg-gpu39)
Average GPU usage   : 49.2% (pg-gpu39)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
